Specialized Green Chemo-Enzymatic Synthesis Solutions

Member of the California Life Sciences and Biocom

We’re pleased to announce that Cassia, LLC now delivers high‑confidence LC‑MS and LC‑MS/MS–based RNA modification profiling designed for teams that require reliable, reproducible results on timelines that support clear decisions. Our new validated workflows provide sensitive, precise, and quantitative detection of nucleoside modifications across mRNA, rRNA, tRNA, as well as custom‑synthesized RNA, with 60–80% RNA coverage. We offer flexible, customizable panels — spanning methylation, acetylation, prenylation, pseudouridylation, and more — and can tailor assay parameters to your scientific and program objectives.

RNA modifications regulate RNA processing, translation efficiency, stability, and cellular stress responses; aberrant patterns are increasingly implicated in oncology, neurological disease, mitochondrial disorders, and mechanisms of RNA‑targeted therapeutics. Cassia’s new mass spectrometry services deliver rigorous qualitative and quantitative insights across biological conditions, model systems, and treatment states — enabling confident interpretation and actionable next steps. Cassia, LLC delivers reliable results, collaborative service, and the scientific rigor required to accelerate meaningful discovery.

Backed by deep technical expertise and cutting‑edge instrumentation, we provide accuracy, flexibility, and collaborative service to accelerate discovery — whether your goals involve elucidating mechanisms, identifying biomarkers, or advancing therapeutic development.

Contact the experts at Cassia, LLC to learn more about our RNA analysis services.

Summary – Galectins are glycan-binding proteins translating the sugar-encoded information of cellular glycoconjugates into physiological activities, including immunity, cell migration, and signaling. Galectins also interact with non-glycosylated partners in the extracellular milieu, among which the pre-B cell receptor (pre-BCR) during B cell development. Here, we perform NMR experiments on native membranes to monitor Gal-1 binding to physiological cell surface ligands. We show that pre-BCR interaction changes Gal-1 binding to glycosylated pre-B cell surface receptors. At the molecular and cellular levels, we identify α-2,3-sialylated motifs as key targeted epitopes. This targeting occurs through a selectivity switch increasing Gal-1 contacts with α-2,3-sialylated poly-N-acetyllactosamine upon pre-BCR interaction. Importantly, we observe that this switch is involved in the regulation of pre-BCR activation. Altogether, this study demonstrates that interactions to non-glycosylated proteins regulate the glycan-decoding functions of galectins at the cell surface. [Cell Reports 2024, 48(8), 114541.]

Advance your biomedical research industry with help from CASSIA LLC. Founded in 2004, we are a privately held biotechnology company and clinical research organization (CRO) specializing in green chemo-enzymatic synthesis solutions for preparing stable isotope-labeled (D, C-13, N-15, O-17/18) metabolites, proteins, nucleic acids, and their analogs. 

Leveraging our unique core technology platforms and expertise, we bring responsible, cost-effective, and creative solutions to a variety of basic, translational, and biomedical research applications, such as: 

• MS 
• NMR 
• Assay Development 
• Metabolic Research 

CASSIA LLC laboratories are located in an eight-building, 150,700 sq. ft. research and development (R&D) business park in the Mira Mesa region of San Diego, CA. We occupy 1580 sq. ft. and are capable of carrying out both basic and applied research in: 

• Molecular Biology 
• Biocatalysis 
• Organic Synthesis 
• Protein and Nucleic Acid Production 

Contact us today to learn more about our biotechnology company and the products and services we provide.